The Law Offices of Omar Figueroa is a boutique California law firm focusing on cannabis law. We fight for justice and human rights, and advocate passionately for our clients every step of the way.
by Omar Figueroa and Lauren Mendelsohn December 10, 2024 On December 3, 2024, a federal court in Texas issued a nationwide preliminary injunction suspending the reporting obligations of the Corporate Transparency Act. The opinion in Texas Top Cop Shop v. Garland can be read below and downloaded here. On […]
by Omar Figueroa and Lauren Mendelsohn December 6, 2024 On December 3, 2024, a federal court in Texas issued a nationwide temporary injunction suspending the reporting obligations of the Corporate Transparency Act. The opinion in Texas Top Cop Shop v. Garland can be read below and downloaded here. This […]
by Omar Figueroa & Lauren Mendelsohn December 2, 2024 UPDATE: On, December 3, 2024, a federal court issued a nationwide temporary injunction forbidding enforcement of the Corporate Transparency Act, as detailed in our subsequent blog post which you can read here. In recent years, the U.S. government has […]
by Omar Figueroa and Lauren Mendelsohn October 29, 2024 On October 29, 2024, the California Court of Appeal for the Second Appellate District, Division 6 issued an astonishing opinion that could have widespread ramifications for the cannabis industry. The appellate decision starts as follows: Many Californians have high expectations that […]
By Lauren Mendelsohn and Omar Figueroa May 21, 2024 Today, the United States Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) officially posted the Notice of Proposed Rulemaking (NPRM) of the intent to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). […]
by Omar Figueroa and Lauren Mendelsohn May 16, 2024 On May 16, 2024, the Biden Administration announced that the United States Department of Justice is taking the next step in the reclassification of cannabis from a Schedule I controlled substance to a Schedule III controlled substance — which would […]
by Omar Figueroa & Lauren Mendelsohn May 6, 2024 In recent years, the U.S. government has introduced several measures to combat illicit financial activities, with the Corporate Transparency Act (CTA) of 2019 being one of the most significant. Aimed at enhancing transparency within legal entities such as corporations and […]
by Omar Figueroa & Lauren Mendelsohn May 2, 2024 We recently wrote that the Drug Enforcement Administration will move to reclassify marijuana as a Schedule III controlled substance. A recent update by the Congressional Research Service makes clear that rescheduling is predicted to result in significant federal tax relief […]
by Omar Figueroa & Lauren Mendelsohn May 1, 2024 Yesterday, we wrote that the Drug Enforcement Administration is anticipated to support the reclassification of marijuana from a Schedule I to a Schedule III controlled substance. Today, the Congressional Research Service issued an updated report on the Legal Consequences of Rescheduling […]
by Omar Figueroa and Lauren Mendelsohn April 30, 2024 On April 30, 2024, the Associated Press reported that the “U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug.” The proposal would “not legalize marijuana outright for recreational use” but “would move marijuana from its current […]